Assembly Biosciences (NASDAQ:ASMB) Trading Down 6% – Here’s Why

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price fell 6% during trading on Tuesday . The company traded as low as $33.66 and last traded at $34.01. 22,687 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 76,965 shares. The stock had previously closed at $36.18.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ASMB. JMP Securities initiated coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set a “market outperform” rating and a $38.00 target price on the stock. Mizuho set a $40.00 price objective on Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. Guggenheim raised their price objective on Assembly Biosciences from $31.00 to $39.00 and gave the company a “buy” rating in a research report on Monday, September 8th. Citizens Jmp assumed coverage on Assembly Biosciences in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $38.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research report on Monday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Assembly Biosciences Stock Up 3.1%

The company has a market capitalization of $533.61 million, a PE ratio of -7.04 and a beta of 1.14. The business has a 50 day simple moving average of $33.63 and a 200 day simple moving average of $25.78.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The business had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $7.46 million. Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%. Equities analysts expect that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its holdings in shares of Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the last quarter. American Century Companies Inc. purchased a new position in Assembly Biosciences in the 1st quarter worth $113,000. Acadian Asset Management LLC lifted its position in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares during the period. Qube Research & Technologies Ltd purchased a new stake in Assembly Biosciences during the 3rd quarter valued at about $282,000. Finally, Palumbo Wealth Management LLC grew its stake in Assembly Biosciences by 3.8% during the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 681 shares during the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.